Table 1.

Univariate Analysis on Incidence of TRMN

Variable	Reference Level	Class Level	HR (95% CI)	P Value
Age	Continuous variable		−0.06 (−0.93 to 0.80)	0.886
Gender	f	m	4.30 (−13.12 to 21.72)	0.631
Karyotype	Normal	Other	−7.37 (−33.47 to 18.73)	0.583
		Complex	−19.15 (−46.22 to 7.92)	0.173
		Diploid	−7.90 (−43.71 to 27.91)	0.668
FISH high risk	No	Yes	−1.05 (−12.36 to 10.25)	0.856
Hypogammaglobulinemia	No	Yes	9.56 (−9.45 to 28.58)	0.332
Persistence of cytopenia	No	Yes resolved	−25.17 (−46.49 to −3.85)	0.026
		Yes nonresolved	−35.05 (−51.33 to −18.76)	<0.001
		Yes	−32.66 (−48.28 to −17.04)	<0.001
Long last cytopenia	No	Yes	−10.84 (−30.18 to 8.49)	0.280
Type of frontline therapy	FC	FCR	5.61 (−20.64 to 31.86)	0.671
Number of FCR cycles	<6	6	3.21 (−12.67 to 19.48)	0.714

CI = confidence interval; f = female; FC = fludarabine or cyclophosphamide; FCR = fludarabine or cyclophosphamide or rituximab; HR = hazard ratio; m = male; TRMN = therapy-related myeloid neoplasms.